hydroxychloroquine has been researched along with Infections in 9 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Infections: Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite the large burden of infection, effective and safe preventative care such as universal hydroxychloroquine use and vaccination are underutilized." | 5.05 | Systemic lupus erythematosus and risk of infection. ( Barber, MRW; Clarke, AE, 2020) |
| "The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with regard to the infectious and gastrointestinal (GI) adverse events (AEs) reported in The Rheumatoid Arthritis Comparison of Active Therapies Trial." | 2.84 | Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events. ( Brophy, MT; Chang, BH; Hannagan, K; O'Dell, JR; Quach, LT; Soe Thwin, S, 2017) |
| "The main determinants of infection in SLE are disease activity, organ damage, and often inevitable medication." | 1.91 | Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. ( He, J; Li, Z, 2023) |
| "To examine the epidemiology of serious infections, a significant cause of morbidity and mortality in systemic lupus erythematosus (SLE), in a nationwide cohort of SLE and lupus nephritis (LN) patients." | 1.42 | Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. ( Costenbader, KH; Feldman, CH; Franklin, JM; Hiraki, LT; Kim, SC; Marty, FM; Winkelmayer, WC, 2015) |
| "She also had developed anasarca two years prior to presentation." | 1.39 | Systemic lupus erythematosus and granulomatous lymphadenopathy. ( Dhakal, AK; Shah, SC; Shakya, A; Shakya, H; Shiva, RK; Shrestha, D, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| He, J | 1 |
| Li, Z | 1 |
| Barber, MRW | 1 |
| Clarke, AE | 1 |
| Lorenzo-Vizcaya, A | 1 |
| Isenberg, D | 1 |
| Novikov, PI | 1 |
| Bulanov, NM | 1 |
| Zykova, AS | 1 |
| Moiseev, SV | 1 |
| Kronbichler, A | 1 |
| Jayne, D | 1 |
| Shrestha, D | 1 |
| Dhakal, AK | 1 |
| Shiva, RK | 1 |
| Shakya, A | 1 |
| Shah, SC | 1 |
| Shakya, H | 1 |
| Feldman, CH | 1 |
| Hiraki, LT | 1 |
| Winkelmayer, WC | 1 |
| Marty, FM | 1 |
| Franklin, JM | 1 |
| Kim, SC | 1 |
| Costenbader, KH | 1 |
| Quach, LT | 1 |
| Chang, BH | 1 |
| Brophy, MT | 1 |
| Soe Thwin, S | 1 |
| Hannagan, K | 1 |
| O'Dell, JR | 1 |
| Al-Mayouf, SM | 1 |
| Ghonaium, A | 1 |
| Bahabri, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy[NCT00405275] | 353 participants (Actual) | Interventional | 2007-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Average difference between 48-week and Baseline DAS28.~The Disease Activity Score for 28 Joints (DAS28) is a well-validated composite outcome measure ranging from 2-10 (higher scores indicating more disease) that incorporates a tender and swollen joint count of 28 joints, a laboratory measure of systemic inflammation (ESR) and a patient-reported general assessment of health on a visual analog scale (ranging from 0-10cm) all into one measure.~Low disease activity is defined as DAS28 ≤ 3.2 units." (NCT00405275)
Timeframe: 48 weeks after baseline assessment
| Intervention | units on a scale (Mean) |
|---|---|
| Triple | -2.12 |
| Etanercept | -2.29 |
1 review available for hydroxychloroquine and Infections
| Article | Year |
|---|---|
Systemic lupus erythematosus and risk of infection.
Topics: Humans; Hydroxychloroquine; Immunosuppression Therapy; Immunosuppressive Agents; Infection Control; | 2020 |
1 trial available for hydroxychloroquine and Infections
| Article | Year |
|---|---|
Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
Topics: Abscess; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etaner | 2017 |
7 other studies available for hydroxychloroquine and Infections
| Article | Year |
|---|---|
Dilemma of immunosuppression and infection risk in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Humans; Hydroxychloroquine; Immunosuppression Therapy; Immunosuppressive Ag | 2023 |
Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom.
Topics: Adult; Antirheumatic Agents; Azathioprine; Cardiovascular Diseases; Cause of Death; Cohort Studies; | 2021 |
Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine.
Topics: Antibodies, Antineutrophil Cytoplasmic; Cytoplasm; Humans; Hydroxychloroquine; Infections; Rituximab | 2020 |
Response to: 'Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine' by Novikov
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cytoplasm; Humans; Hydroxychloroquine; I | 2020 |
Systemic lupus erythematosus and granulomatous lymphadenopathy.
Topics: Antibodies, Antinuclear; Child; Connective Tissue Diseases; Diagnosis, Differential; Disease Progres | 2013 |
Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis.
Topics: Adolescent; Adult; Antirheumatic Agents; Black or African American; Cohort Studies; Female; Glucocor | 2015 |
Hypergammaglobulinaemic purpura associated with IgG subclass imbalance and recurrent infection.
Topics: Child, Preschool; Disease Progression; Humans; Hydroxychloroquine; Immunoglobulin G; Infections; Mal | 2000 |